key: cord-0998559-7pt1gq5d
authors: Garcia, M. A.; Barreras, P. V.; Lewis, A.; Pinilla, G.; Sokoll, L. J.; Kickler, T.; Mostafa, H.; Caturegli, M.; Moghekar, A.; Fitzgerald, K. C.; Hopkins Neuro-COVID-19 Group,; Pardo, C. A.
title: Cerebrospinal fluid in COVID-19 neurological complications: no cytokine storm or neuroinflammation.
date: 2021-01-12
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2021.01.10.20249014
sha: 819c08e8995b733fdca5654c126893fa052e5f46
doc_id: 998559
cord_uid: 7pt1gq5d

BACKGROUND. Neurological complications occur in COVID-19. We aimed to examine cerebrospinal fluid (CSF) of COVID-19 subjects with neurological complications and determine presence of neuroinflammatory changes implicated in pathogenesis. METHODS. Cross-sectional study of CSF neuroinflammatory profiles from 18 COVID-19 subjects with neurological complications categorized by diagnosis (stroke, encephalopathy, headache) and illness severity (critical, severe, moderate, mild). COVID-19 CSF was compared with CSF from healthy, infectious and neuroinflammatory disorders and stroke controls (n=82). Cytokines (IL-6, TNF-alpha, IFN-gamma, IL-10, IL-12p70, IL-17A), inflammation and coagulation markers (high-sensitivity-C Reactive Protein [hsCRP], ferritin, fibrinogen, D-dimer, Factor VIII) and neurofilament light chain (NF-L), were quantified. SARS-CoV2 RNA and SARS-CoV2 IgG and IgA antibodies in CSF were tested with RT-PCR and ELISA. RESULTS. CSF from COVID-19 subjects showed a paucity of neuroinflammatory changes, absence of pleocytosis or specific increases in pro-inflammatory markers or cytokines (IL-6, ferritin, or D-dimer). Anti-SARS-CoV2 antibodies in CSF of COVID-19 subjects (77%) were observed despite no evidence of SARS-CoV2 viral RNA. A similar increase of pro-inflammatory cytokines (IL-6, TNF-alpha;, IL-12p70) and IL-10 in CSF of COVID-19 and non-COVID-19 stroke subjects was observed compared to controls. CSF-NF-L was elevated in subjects with stroke and critical COVID-19. CSF-hsCRP was present almost exclusively in COVID-19 cases. CONCLUSION. The paucity of neuroinflammatory changes in CSF of COVID-19 subjects and lack of SARS-CoV2 RNA do not support the presumed neurovirulence of SARS-CoV2 or neuroinflammation in pathogenesis of neurological complications in COVID-19. Elevated CSF-NF-L indicates neuroaxonal injury in COVID-19 cases. The role of CSF SARS-CoV2 IgG antibodies is still undetermined.

12p70, IL-17A), inflammation and coagulation markers (high-sensitivity-C Reactive Protein (hsCRP), ferritin, fibrinogen, D-dimer, Factor VIII) and neurofilament light chain (NF-L). We compared the CSF from subjects with COVID-19 associated neurological complications with CSF of non-COVID-19 subjects with neurological infections, neuroinflammatory disorders and stroke to compare the immune profiles which may allow the recognition of common pathogenic pathways. The description of CSF analytes in the COVID-19 diagnostic groups and control groups are included in Table 3 . Comparative analysis and statistical outcomes for all CSF analytes is shown in Figure 2 . A representative heat map of the P value significance for all analyte comparisons between the COVID-19 diagnostic categories, disease severity and timing of CSF collection with the control groups are described in Figure 3 . No significant differences in the CSF WCC and protein concentrations between the three diagnostic categories of the COVID-19 neurological problems were found. As compared with healthy controls, there were no significant differences in the WCC and protein concentration with exception of the COVID-19 headache group which had a significantly lower protein concentration. Overall, the WCC and protein concentrations were lower in COVID-19 cases as compared with neuroinflammatory controls. No significant differences were seen between COVID-19 and non-COVID-19 stroke cases.

Quantification of neurofilament light chain (NF-L) in CSF was used as indicator of neuroaxonal damage in COVID-19 and control subjects. When comparing based on severity, CSF NF-L levels were significantly elevated in the critical COVID-19 group compared to the other severity categories. CSF concentrations of NF-L were also markedly elevated in the COVID-19 stroke group as compared with healthy controls (P=< 0.001) and the COVID-19 headache group (P=< 0.01). Although the COVID-19 encephalopathy group had an elevated median NF-L concentration of 8408 pg/mL, compared to 1105 pg/mL of the healthy control group, this involved in severe and critical COVID-19. (35) (36) (37) (38) The concentrations, comparative analysis and statistical significance between COVID-19 groups and controls for all 6 cytokines analyzed are described in Table 3, and Figures 2 and 3. The sensitivity of the assay for detection of the of the six cytokines across all CSF diagnostic groups is described in supplemental Table 3 . Analysis of cytokines levels within the COVID-19 diagnostic categories showed that only TNFa in the COVID-19 stroke group was significantly increased compared to the headache group (P=0.03). When the COVID-19 diagnostic groups were compared with controls, the COVID-19 stroke group had significant elevated concentrations of IL-6, TNFa, IL-10 and IL-12p70 as compared with the healthy control group. None of the COVID-19 diagnostic groups, including the stroke group, showed any significant increase of cytokines as compared with neuroinflammatory or non-COVID-19 stroke control groups. Instead, significant increased concentrations of selected cytokines such as TNFa and IFNg were noted in neuroinflammatory groups such as acute meningitis and encephalitis as compared with the COVID-19 stroke and encephalopathy groups. IFNg and IL-17A concentrations were reduced in COVID-19 CSF as compared with inflammatory control groups such as acute meningitis, encephalitis and neurosarcoidosis ( Figure 3A ). To determine whether such pattern of cytokines was specific to the COVID-19 stroke group, we analyzed separately the cytokine profiles of the non-COVID-19 stroke group with other control groups. We found the non-COVID-19 stroke group had significant increases in the concentrations of IL6, TNFa, IL-10 and IL-12p70 as compared with the healthy control group, and reduced levels of IFNg and IL-17A as compared with acute meningitis groups ( Figure 3D ), a profile similar to the one observed in the COVID-19 stroke group. Cytokines profiles as related with COVID-19 disease severity and timing of CSF collection are summarized in the statistical significance heatmap illustrated in Figure 3 . When COVID-19 subjects were categorized by disease severity, the critical illness group (n=8) had significantly increased levels of IL-10 and IL-12p70 when compared with healthy controls ( Figure   3B ). The timing of CSF collection did not show any significant change in the profile of COVID-19 cytokines with exception of an increased IL-12p70 in the "early" COVID-19 CSF sampling group as compared with healthy controls ( Figure 3C ). Interestingly, analysis of the COVID-19 subjects with C-HIS (n=6), which is characterized by marked systemic inflammatory response or "cytokine storm" (27) , showed that CSF cytokine levels did not have any significant differences with the healthy control group. However, an analysis within the COVID-19 group showed levels of IL-6 and IL-10 were significantly elevated (P=0.02 and 0.01 respectively) while concentrations of INFg and IL-12p70 were All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint significantly lower (P=0.04 for both cytokines) in the COVID-19 C-HIS cases (n=6) when compared with other non-H-CIS COVID-19 cases (n=12). Interestingly, the concentration of IL-6 in the CSF of COVID-19 cases did not correlate with the corresponding serum IL-6 (P=0.27). The effect of specific treatments (e.g., steroids, antivirals) on CSF inflammatory markers was also evaluated. Of the 18 patients included in our cohort of COVID-19 subjects, only 2 subjects (1 and 2, Table 1 ) had received steroids during the 5 days preceding the lumbar puncture. None of the COVID-19 patients received any of the experimental drugs used during the period prior to CSF collection.

Acute phase reactants such as ferritin, C-reactive protein (CRP) and coagulation markers including D-dimer, fibrinogen and factor VIII, have been associated to be markers of severe and critical COVID-19. (39-42) To investigate if they are associated with mechanisms of neurological involvement in COVID-19, we quantified such markers in the CSF of COVID-19 subjects and controls. Using a high-sensitive CRP (hsCRP) assay, we found that CRP was present almost exclusively in the CSF of COVID-19 subjects as it was detected in 7/18 subjects, 4 COVID-19 encephalopathy and 3 COVID-19 stroke, while only one CSF (from an autoimmune encephalitis subject) of the 82 CSF controls had detectable hsCRP (P= 0.001). CSF hsCRP levels strongly correlated with CRP serum levels (P=0.001, Spearman's r 0.765). CSF hsCRP was present only in critical or severe COVID-19 subjects and was elevated in 5 of 6 subjects with COVID-19 C-HIS. In contrast, while the CSF ferritin had a 100% detection rate in the CSF of all COVID-19 and comparison groups (Table 3) , there was not significant difference between the concentrations of CSF ferritin when COVID-19 diagnostic groups were compared with healthy, neuroinflammatory or stroke controls. However, an analysis within the COVID-19 diagnostic categories showed the stroke group had significantly elevated levels of CSF ferritin as compared with the headache group (P=0.04). Interestingly, analysis of COVID-19 categorized by disease severity showed that CSF ferritin levels in severe COVID-19 subjects were significantly increased as compared with healthy controls and NMO cases ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint was present in 4 COVID-19 stroke subjects and in 25 of the CSF controls (P=0.06). CSF D-dimer was not significantly different between COVID-19 groups and healthy controls. Instead, CSF D-dimer in cases of acute meningitis and neurosarcoidosis was significantly increased as compared with COVID-19 encephalopathy cases. Markers of coagulation such as fibrinogen and Factor VIII were undetectable in the CSF of COVID-19 subjects and comparison controls.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint

In contrast with prevailing assumptions, our study reveals a paucity of neuroinflammatory changes as reflected by the lack of specific increases in CSF pro-inflammatory cytokines or markers of systemic inflammation such as IL-6, ferritin, or D-dimer as typically seen in serum of COVID-19 patients. These findings paralleled a lack of cellular responses like pleocytosis or other markers of immunological activity within the CNS such as increase in IgG index or OCBs. The absence of meaningful neuroinflammatory changes in the CSF of COVID-19 cases is further demonstrated when it is compared to CSF from acute infectious or autoimmune neuroinflammatory pathologies that show significantly greater inflammatory changes. Our study also reveals: 1) a prominent presence of SARS-CoV2 antibodies in absence of SARS-CoV2 viral RNA in the CSF of subjects with COVID-19 neurological complications;

2) elevated levels of CSF hsCRP in a subset of subjects with critical and severe COVID-19 illness; 3) marked increase in CSF NF-L, a marker of neuroaxonal injury in cases of critical COVID-19 illness and stroke; 4) an essentially equivalent increase of a subset of pro-inflammatory cytokines in the CSF in cases of COVID-19 stroke and non-COVID-19 stroke subjects.

The lack of CSF pleocytosis in COVID-19 subjects, normal protein, and absence of abnormalities in IgG index or Q(Alb), concurs with other studies (16) (17) (18) (19) (20) . This paucity of CSF inflammatory changes undermines the hypothesis that conventional neuroinflammatory or encephalitic processes play roles in the pathogenesis of the most common neurological complications associated with COVID-19 that were studied here. Furthermore, our case-control study approach of CSF immune markers showed that in subjects with COVID-19 who experienced complications such as stroke or encephalopathy, most of the CSF changes appear to be determined by other pathologies such as ischemic disease likely driven by systemic or vascular factors that influence the development of such brain pathologies rather than primary neuroimmune mediated processes. An important caveat is that we did not test the full spectrum of reported neurologic complications in COVID-19, including multiple cranial neuropathies, ADEM, or GBS, and CSF analysis in those conditions may show different results.

We failed to detect SARS-CoV2 viral RNA in the CSF of all COVID-19 subjects examined, concurring with other studies (16, (18) (19) (20) (21) . The lack of SARS-CoV2 RNA in the CSF may be interpreted as lack of neuro-invasiveness, absence of active viral replication or simply a relatively low viral trafficking into the CNS. Although the detection of RNA viruses in CSF has been historically challenging in some viral disorders of the CNS,(45) the absence of viral RNA along with the lack of pleocytosis and other inflammatory changes in the CSF of COVID-19 patients supports the conclusion that there is not an active trafficking of SARS-CoV2 into the CNS causing neuroinflammation. This distinguishes it from other RNA viruses like poliomyelitis, enterovirus, West-Nile virus that are difficult to detect but produce blatant signs of neuroinflammation in the CSF (45) (46) (47) .

A noteworthy observation in our study is a high prevalence (77%) of SARS-CoV2 spike IgG antibodies in the CSF of COVID-19 cases. Given the absence of viral RNA in the CSF, the lack of pleocytosis which may facilitate B-cells trafficking into the CNS, and absence of intrathecal IgG production (e.g., IgG index, OCBs), CSF antibodies to SARS-CoV2 likely originate from serum and then transfer into the CNS despite an otherwise intact blood-CSF barrier, as occurs in other CNS pathologies .(48) Alternatively, stroke or ischemic changes may have altered the CSF-blood brain barrier to facilitate permeability of IgG antibodies. Presence of SARS-CoV2 antibodies in CSF has been also reported by previous studies which raises the possibility that they are directly pathogenic in the neurological complications of COVID-19 (22, 49) . In a prior study of eight encephalopathic or comatose patients with COVID-19, a high titer of SARS-CoV2 IgG was observed in 50% of them, with one patient showing an increased IgG index (22) .

Another study of 3 patients with COVID-19 critical illness found evidence of SARS-CoV2 IgM in the CSF (49) . In our study, the presence of SARS-CoV2 antibodies was not associated with specific COVID-19 diagnostic group or disease severity. Although 7 of 13 COVID-19 subjects with positive SARS-CoV2 antibodies in the CSF had potential "contamination" from blood derived from SAH, stroke or a traumatic lumbar puncture, six -did not exhibit any meaningful WCC or RBC presence. Future studies looking for sites of SARS-CoV2 antibody cross reactivity in the CNS, potential neurological effects or pathologic potential in animal models, would be helpful to clarify this question.

Notably, our study showed an impressive lack of pro-inflammatory cytokines in the CSF of subjects with COVID-19 neurological problems. With the exception of COVID-19 stroke cases, COVID-19 encephalopathy or headache cases did not show a noticeable pro-inflammatory cytokine response in the CSF as compared with controls. This observation suggests that local increases of pro-inflammatory cytokines are unlikely the pathogenic factors associated with the neurological symptoms observed in COVID-19 encephalopathy or headache. Only the CSF of the COVID-19 stroke All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint group appeared to have significant increase in IL-6, TNFa, IL10 and IL-12p70 as compared with the healthy control group and the COVID-19 headache group. However, these cytokine increases were largely equivalent in the non-COVID-19 stroke controls, suggesting that the cytokine increases in the brain of COVID-19 stroke subjects are likely driven by stroke and ischemic pathology (50-52) rather than specific neuroinflammatory changes associated with COVID-19. Furthermore, CSF from subjects with C-HIS showed not increases in proinflammatory cytokines as compared with healthy controls although increases in IL-6 and IL-10 and lower IFNg and IL12p70 differentiate them from non-C-HIS subjects. NF-L, a marker of neuroaxonal injury, was increased in stroke and critical COVID-19 cases, and within the COVID-19 cases, it was elevated in stroke and encephalopathy compared to the headache group.

Such observation emphasizes the fact that in critical and severe COVID-19 encephalopathy cases, a process of neuronal injury occurs even in absence of neuroimaging evidence of stroke or ischemic injury and may suggest that such neuronal damage is associated with ischemia, hypoxia and systemic illness. Such finding concurs with previous observations of elevation of neuronal and glial proteins in the CSF in the setting of critical COVID-19 illness and support the approach for using such proteins as potential biomarkers of disease process and outcome in future serological studies. (53, 54) Remarkably, our study demonstrated absent parallel increase in CSF of markers such as IL-6, ferritin, D-dimer or coagulation factors as it has been observed in the serum of COVID-19 patients. A notable exception was the presence of detectable levels of CSF hsCRP in a subset of subjects with critical and severe COVID-19 illness, stroke and encephalopathy, which correlated with the magnitude of corresponding serum increase. The upsurge of CSF hsCRP in COVID-19 subjects suggests that such acute phase reactant is linked to the mechanisms of stroke and ischemia during acute and subacute stages of COVID-19. It is uncertain if CRP in CSF is actively or passively transported from serum, due to brain endothelial pathology or from brain disease processes, as neurons may have capability to produce such pentraxin. (55) Future studies should focus on determining the role of CRP in CSF, establishing the outcome of neurological disease in COVID-19 subjects when CSF hsCRP is detected as its presence may have long-term implications in mechanisms of neurodegeneration (55) . Surprisingly, levels of CSF ferritin and D-dimer, showed no significant increase and/or did not mirror the marked elevation observed in the serum levels in COVID-19 subjects.

CSF ferritin and D-dimer levels were elevated in COVID-19 cases mostly due to the presence of cases of SAH or All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint stroke with ICH. Remarkably, standard assays for quantification of fibrinogen and factor VIII in CSF failed to detect such analytes in both COVID-19 and control cases including stroke cases, findings that suggest either the absence of such molecules in the CSF or the lack of sensitivity of the assay for their detection.

Although the prospect of a consensus for common CSF signatures in patients with neurological manifestations of COVID-19 is challenged by the diversity of clinical presentations, patient heterogeneity, overlapping risk factors and co-morbidities, our study has further implications for the understanding of the neuropathogenesis of these neurological complications. The paucity of neuroinflammatory changes in COVID-19 CSF rejects the prevailing assumption that pro-inflammatory cytokines, primary neuroinflammation or SARS-CoV2 neurovirulence are the main drivers of neuropathogenesis in COVID-19. We believe the few identified "neuroinflammatory" processes in the CSF of COVID-19 (23, 24, 56) animal studies will be helpful to elucidate these mechanisms. Another interesting future direction will be to investigate the potential role of SARS-CoV2 antibodies in the pathogenesis of acute, subacute or even long-term consequences of COVID-19 and effect on CNS function including in those cases of the reported "brain fog" and other neurological symptoms in the so-called "long term haulers" (59) .

The strengths of this study include a comprehensive analysis of markers of disease immunopathogenesis in the CSF from COVID-19 subjects as compared with CSF from healthy controls, stroke and neuroinflammatory disorders subjects, and a comprehensive clinical, neuroimaging and laboratory phenotyping of the subjects, but a few limitations are important to mention. First, we mainly evaluated cytokines and immune factors which were selected based on their previously reported relevance to COVID-19. This was a limited study of paired CSF-serum samples for cytokine and antibody profiling. This was a necessary impediment because the limited availability of CSF and blood samples for All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint testing. Moreover, during the period of the study, blood sampling in many patients with COVID-19 in a critical or severe stage was restricted to standard diagnostic testing. Second, this study is limited to the clinical experience in a tertiary referral center, a relatively small cohort of patients accrued during a short period of time and a small sample size for the relatively high number of comparisons. Finally, and more generally, future multi-center studies should include well acquired and phenotyped CSF repository samples that allow the expansion of analytical approaches of the CSF to determine pathogenic factors involved in the neurological complications during acute and long-term consequences of COVID-19.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ;

The CSF characteristics of a cross-sectional cohort of 18 hospitalized adult COVID-19 patients with neurological manifestations, were compared to those of 14 age matched healthy and 68 non-COVID-19 neurological disease controls to investigate immune and neuroinflammatory changes in the CSF which may be associated with pathogenesis of neurological involvement. The sample size of the COVID-19 group was determined by convenience and it corresponds to all COVID-19 patients that underwent CSF analysis during the period of study at our institution. The (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint Guidelines (61) and defined as follows: 1) Critical illness: respiratory failure, septic shock, and/or multiple organ dysfunction 2) Severe illness: respiratory frequency >30 breaths per minute, oxygen saturation (SaO2) ≤93% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mmHg or lung infiltrates >50%; 3) Moderate illness: Evidence of lower respiratory disease by clinical assessment or imaging and SaO2 >93% on room air at sea level and 4) Mild Illness: Individuals who had any of various signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain) without shortness of breath, dyspnea, or abnormal imaging. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. Statistics: Continuous variables were described using medians and interquartile ranges, while categorical features with percentages. Planned comparisons between COVID-19 and control groups were performed using Mann-Whitney test.

All 3 COVID-19 diagnostic categories were compared with each control group and with each other. For CSF hsCRP and D-dimer, outputs were dichotomized with 0.2 mg/L as the cut-off considering the bimodal concentrations found; An initial global test assessed differences in groups and was followed by individual Fisher's exact tests for comparison among groups. For analysis of cytokines, values with a coefficient of variation higher than 30% were disregarded.

Missing concentration values below the lower limit of detection were calculated by dividing the lower limit of quantification (LLOQ) corresponding for each cytokine by the square root of 2. Spearman's correlation coefficient (Rho; ρ) was evaluated as well for relating NF-light concentrations with the other immunomarkers. Significant p values were set below 0.05. We specified our primary analyses as global tests comparing COVID-19 groups versus healthy and neurologic disease controls, and we considered our study to be exploratory in nature. As a result, we did not adjust for multiple comparisons. Analytes other than cytokines were analyzed with the obtained raw data. Statistical analysis was performed in Stata v.14. (StataCorp, Texas, USA).

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint

We would like to thank all patients and/or their families for giving consent for clinical information and sample collection for this study. Additionally, we want to thank the clinical and laboratory teams for their assistance in the evaluation of patients and sample collection, as well as the hospital staff for their dedication in the fight of COVID-19. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 12, 2021. ; https://doi.org/10.1101/2021.01.10.20249014 doi: medRxiv preprint

Profiles of inflammatory markers in the CSF from 18 COVID-19 subjects categorized by diagnosis (yellow box) as compared with healthy controls (n= 14), acute meningitis (n=12) and encephalitis (n=14), autoimmune encephalitis (n=12), neuromyelitis optica (n=11) and neurosarcoidosis (n=14) and non-COVID-19 strokes (n=8). Boxes indicate the interquartile range and whiskers show the minimum and maximum values for each group, and median (red line in box plot). P> 0.05 is denoted as an orange line when COVID-19 diagnostic group was significantly higher than the control and as a blue line when the control group was significantly higher than the COVID-19 diagnostic category.

Significance for D-dimer and hsCRP was obtained by categorical analysis, present or absent. The significance for hsCRP was represented by the COVID-19 stroke and encephalopathy groups (yellow bracket) vs. the healthy controls and the overall disease control groups (gray bracket). All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Significance for D-dimer and hsCRP was obtained by categorical analysis, present or absent. 

Lifting the mask on neurological manifestations of COVID-19

Neurological associations of COVID-19

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings

A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients

Neurologic Features in Severe SARS-CoV-2 Infection. The New England journal of medicine

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry

COVID-19 impact on consecutive neurological patients admitted to the emergency department

COVID-19-associated acute disseminated encephalomyelitis (ADEM)

Miller Fisher syndrome and polyneuritis cranialis in COVID-19

Guillain-Barré Syndrome Associated with SARS-CoV-2. The New England journal of medicine

Guillain-Barré syndrome in SARS-CoV-2 infection: an instant systematic review of the first six months of pandemic

A prospective clinical study of detailed neurological manifestations in patients with COVID-19

Headache in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Narrative Review. Headache: The Journal of Head and Face Pain

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution

Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development

Isolated intracranial hypertension associated with COVID-19

Cerebrospinal Analysis in Patients With COVID-19. Open forum infectious diseases

Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients

Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms

Cerebrospinal fluid features in COVID-19 patients with neurologic manifestations: correlation with brain MRI findings in 58 patients. The Journal of infectious diseases

Anti-SARS-CoV-2 antibodies in the CSF, blood-brain barrier dysfunction, and neurological outcome: Studies in 8 stuporous and comatose patients

Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19

CSF biomarkers in patients with COVID-19 and neurological symptoms: A case series

Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid

Miller-Fisher syndrome after COVID-19: neurochemical markers as an early sign of nervous system involvement

Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study

Correlation Between 3790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates. Clinical Infectious Diseases. 2020. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium

A clinical approach to diagnosis of autoimmune encephalitis

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group

The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping)

An inflammatory cytokine signature predicts COVID-19 severity and survival

Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerging microbes & infections

Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury

COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study

Molecular methods for diagnosis of viral encephalitis

CSF findings in 250 patients with serologically confirmed West Nile virus meningitis and encephalitis

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

The blood-cerebrospinal fluid barrier: structure and functional significance

Encephalopathy and Encephalitis Associated with Cerebrospinal Fluid Cytokine Alterations and Coronavirus Disease

Proinflammatory cytokines and early neurological worsening in ischemic stroke

Inflammatory cytokines in experimental and human stroke

Elevation of cerebrospinal fluid cytokine/chemokines involved in innate, T cell, and granulocyte inflammation in pediatric focal cerebral arteriopathy

Association of neuronal injury blood marker neurofilament light chain with mild-to-moderate COVID-19

Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19

Monomeric C-reactive protein-a key molecule driving development of Alzheimer's disease associated with brain ischaemia?

Reply to the Letter "COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation

Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

As Their Numbers Grow, COVID-19 "Long Haulers

Updated nomenclature of delirium and acute encephalopathy: statement of ten Societies

Duration of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infectivity: When Is It Safe to Discontinue Isolation? Clinical Infectious Diseases

Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder